GlassScriptPhysician profile
Jennifer J Tite
NPI 1396809968
$4,352.34
in general payments reported to CMS, 2019-2025
18 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $806 · 2022: $1,942 · 2023: $1,090 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,308.44 | 2021-2023 | |
| Pfizer INC. | $377.41 | 2021-2025 | |
| Novo Nordisk INC | $375.28 | 2021-2025 | Wegovy, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $312.20 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.16 | 2021-2023 | Xifaxan |
| Genzyme Corporation | $232.26 | 2022-2023 | |
| Gilead Sciences, INC. | $206.09 | 2022-2025 | Livdelzi |
| Celgene Corporation | $199.61 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $195.00 | 2022-2023 | Entyvio |
| Janssen Biotech, INC. | $139.01 | 2022-2023 | Stelara, Remicade, Simponi |
| Nestle Healthcare Nutrition INC. | $127.87 | 2021-2023 | |
| Genentech USA, INC. | $124.01 | 2021 | |
| Janssen Scientific Affairs, LLC | $120.83 | 2022 | |
| Madrigal Pharmaceuticals | $114.80 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $97.51 | 2022-2023 | Dificid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $94.20 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $24.45 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.21 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Tite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.